In this particular study, treatment-related mortality occurred in 5.3% and 1.6% of patients receiving irinotecan weekly and every three weeks, respectively. Determining a patient's genotype status ...

Bristol Myers Squibb BMY announced that it has obtained FDA approval for the label expansion of Opdivo (nivolumab) plus ...

NICE is unable to make a recommendation about the use in the NHS of pegylated liposomal irinotecan plus oxaliplatin, 5-fluorouracil and leucovorin for untreated metastatic pancreatic cancer in adults.

Find all the commercial and brand names of generic drug called Irinotecan. This is an invaluable reference resource for healthcare professionals, patients, caregivers and anyone in need of ...

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic MSI-H/dMMR colorectal cancer.